Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.
📍 The outcome
The FDA selected seven pharmaceutical companies, including Eli Lilly, Regeneron, Fujifilm, and Kriya, for the PreCheck Pilot Program. The initiative aimed to strengthen U.S. drug manufacturing by speeding up the review of new manufacturing facilities.
Epilogue added 43d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has introduced a program designed to speed up the review of new manufacturing facilities to get medicines to market more quickly. Eli Lilly, Regeneron, and Kriya are among the first companies selected to participate in the initiative.
Coverage from CNBC, Reuters, Yahoo, and Business Wire emphasizes the selection of these specific companies for the pilot. The program is identified by Business Wire as the FDA PreCheck Pilot Program.
Future developments involve the implementation of this strategy to reduce timelines for facility reviews and the subsequent delivery of medications to the market.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46d ago.
Who reported it (12)
- FDA selects Lilly, Regeneron, Fujifilm, 4 others for PreCheck Pilot Program Fierce Pharma · 46d ago
- Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme Yahoo Finance · 46d ago
- FDA Picks 7 Pharma Companies for Manufacturing Pilot Powder & Bulk Solids · 46d ago
- Kriya Selected for FDA PreCheck Pilot Program BioSpace · 46d ago
- Eli Lilly (LLY) Joins FDA Pilot Program to Strengthen U.S. Drug Manufacturing GuruFocus · 46d ago
- Eli Lilly (LLY) Joins FDA PreCheck Pilot Program to Enhance Drug Manufacturing GuruFocus · 46d ago
- FDA PreCheck Could Speed Up These 3 U.S. Biopharma Stocks simplywall.st · 46d ago
- Kriya Selected for FDA PreCheck Pilot Program Business Wire · 46d ago
- Lilly, Regeneron selected for US program to review new manufacturing facilities faster, CNBC reports Yahoo · 46d ago
- Lilly, Regeneron selected for US program to review new manufacturing plants faster, CNBC reports Reuters · 46d ago
- A new FDA strategy aims to get medicines to the market faster Baton Rouge Business Report · 46d ago
- Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities CNBC · 46d ago broke it first
Quick answers
Which companies were selected for the FDA initiative?
Eli Lilly, Regeneron, and Kriya are among the companies selected.
What is the goal of this FDA program?
The strategy aims to review new manufacturing facilities faster to get medicines to the market more quickly.
What is the official name of the pilot program?
According to Business Wire, it is the FDA PreCheck Pilot Program.
People, places & organizations
Topics
Related trends
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.